Welcome to the 17th edition of HD Insights, timed for release at the 21st International Congress of Parkinson Disease and Movement Disorders in Vancouver, BC. We continue our mission to promote, disseminate, and facilitate HD research with content that is valuable and informative to the global community of HD researchers.
In this edition, we continue our focus on gene-targeting therapies for HD, and explore other developments in HD therapeutics. We begin with an article about the recent FDA approval of Teva’s deutetrabenazine (AUSTEDO™). Dr. Lise Munsie investigates recent publications on gene-targeted therapies in her “Research Round-up” series. We talk with Dr. Beverly Davidson about her many contributions to gene-silencing therapies for HD and other neurological diseases, and explore the latest in game-changing gene-silencing therapies with Dr. Amber Southwell. Dr. Nicholas Caron reports on the highlights of the CHDI meeting in Malta in April. Dr. Irina Kerkis describes the latest in HD research in Brazil, especially research on stem-cell-based therapies developed with Dr. Monica Haddad. Ms. Jennifer Simpson and Dr. George Yohrling from the HDSA describe the findings of their survey exploring the preferences and priorities of the HD community for HD research, a highlight from the Journal of Huntington’s Disease. Finally, we continue to update the HD community on upcoming, ongoing, and recently completed clinical trials.
This edition marks the last edition of Meredith Achey’s tenure as Deputy Editor. Through boundless energy and dedication, Meredith has helped shape every aspect of HD Insights for the last four years. Only the increasing demands of medical school took her away from her work at HD Insights, and we wish her all the best. We welcome incoming Deputy Editor Sara LaJeunesse to the HD Insights team. Sara comes to us with a wealth of writing, editing, and publishing experience, and we are excited to continue to grow with her leadership.
If you or your colleagues would like a free electronic subscription to HD Insights, please visit www.HDInsights.org and complete the subscription form. We welcome your job postings, scholarship announcements, and other opportunities you would like to share with the HD community. If you have an opportunity you would like to share with nearly 3,000 HD researchers and clinicians, or would like to give us feedback, comments, or contributions, please email us at email@example.com. Thank you.